7/102 sources · 2 publishersUpdated Oct 26, 16:55 UTC
Stifel lifts ORIC Pharmaceuticals price target to $18 on positive ESMO data
Stifel raised its price target for ORIC Pharmaceuticals to $18 from $14 while keeping a Buy rating. The adjustment follows encouraging Phase 1b enozertinib data and reduced risk perception for the MEVPRO‑1 trial presented at ESMO. The stock is trading at $13.17, up 61% year‑to‑date. Other analysts also raised targets, citing pipeline progress.
Why it matters
Stifel’s new $18 target implies about 36.7% upside from the recent close, which may attract buying interest. The higher target reflects analyst confidence in upcoming data, potentially supporting the stock’s momentum.
Key facts
- 1Stifel increased its price target to $18 from $14. investing.com
- 2The current share price is $13.17. investing.com
- 3ORIC is up 61% year‑to‑date. investing.com
- 4Stifel maintained a Buy rating. investing.com
- 5The price target is based on positive Phase 1b enozertinib data and reduced risk for the MEVPRO‑1 trial presented at ESMO. tradingview.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.